Sanofi's Phase 3 eczema data cloud hopes for potential immunology blockbuster
赛诺菲三期湿疹数据为潜在免疫学重磅药带来曙光

The centerpiece of Sanofi’s immunology efforts succeeded in two more Phase 3 eczema studies in the US, the company announced Friday, setting up a possible FDA submission before the end of the year.
赛诺菲周五宣布，其免疫学研发的核心项目在美国又有两项三期湿疹研究取得成功，为在年底前向美国食品药品监督管理局递交申请铺平道路。